Proof of concept for the utility of biologics in advanced pancreas cancer occurred in 2007 when erlotinib, a small molecule inhibitor of the epidermal growth factor receptor (EGFR) pathway, in combination with gemcitabine improved survival for patients over gemcitabine alone [5]. The gene discussed is EGFR; the disease is pancreatic neoplasm.